Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SIRT2-mediated deacetylation activates USP22 catalytic function for PD-L1 protein stabilization and tumor immune escape
Na Li, Qiong Gao, Huijun Jia, Guoqing Xue, Yuanzhang Zhou, Shengnan Wang, Suxian Ma, Bingjin Hu, Zhuoyue Zhao, Chen Su, Yinghong Liu, Wenxuan Xi, Zhonghao Li, Donna D. Zhang, Peng Chu, Zhaolin Sun, Deyu Fang
Na Li, Qiong Gao, Huijun Jia, Guoqing Xue, Yuanzhang Zhou, Shengnan Wang, Suxian Ma, Bingjin Hu, Zhuoyue Zhao, Chen Su, Yinghong Liu, Wenxuan Xi, Zhonghao Li, Donna D. Zhang, Peng Chu, Zhaolin Sun, Deyu Fang
View: Text | PDF
Research Article Immunology Oncology

SIRT2-mediated deacetylation activates USP22 catalytic function for PD-L1 protein stabilization and tumor immune escape

  • Text
  • PDF
Abstract

Immune checkpoint blockade (ICB), including PD-1/PD-L1 inhibitors, has transformed cancer therapy but benefits only a subset of patients. Understanding how PD-L1 is regulated and identifying strategies to overcome resistance remain critical. Here, we identify SIRT2 as a key positive regulator of PD-L1 across multiple human cancers. Unexpectedly, SIRT2 did not act at the transcriptional level but stabilized PD-L1 protein by preventing ubiquitin-mediated degradation. Mechanistically, SIRT2 maintained the protein stability of USP22, a PD-L1 deubiquitinase. Loss of SIRT2 reduced USP22 levels, whereas ectopic USP22 fully rescued PD-L1 expression and reversed the enhanced antitumor immunity induced by SIRT2 inhibition. We further show that SIRT2 directly deacetylates USP22 at K382 and K505 within its catalytic domain, promoting USP22 deubiquitinase activity and protecting both itself and its substrates from degradation. Our findings reveal a molecular mechanism by which an acetylation–deacetylation switch dynamically regulates deubiquitinase catalytic activity. Therapeutically, SIRT2 inhibition synergized with PD-1/PD-L1 blockade and USP22 inhibition to enhance antitumor immunity. Consistently, protein, but not mRNA, levels of SIRT2, USP22, and PD-L1 positively correlated in human bladder cancer and melanoma. Together, these findings define a SIRT2/USP22/PD-L1 axis driving tumor immune evasion and highlight SIRT2 as a promising target to improve ICB efficacy.

Authors

Na Li, Qiong Gao, Huijun Jia, Guoqing Xue, Yuanzhang Zhou, Shengnan Wang, Suxian Ma, Bingjin Hu, Zhuoyue Zhao, Chen Su, Yinghong Liu, Wenxuan Xi, Zhonghao Li, Donna D. Zhang, Peng Chu, Zhaolin Sun, Deyu Fang

×

Figure 6

SIRT2 KO enhances antitumor immunity.

Options: View larger image (or click on image) Download as PowerPoint
SIRT2 KO enhances antitumor immunity.
(A–C) WT and SIRT2-KO MB49 cells w...
(A–C) WT and SIRT2-KO MB49 cells were subcutaneously implanted into the right flanks of C57BL/6J mice (n = 10). Representative images of mouse tumors (B), tumor volume (A), and tumor weight (C). Scale bar: 1 cm. (D) PD-L1 expression of CD45– tumor cells (n = 10). (E) Analysis of CD4+ and CD8+ T cells in a gated CD45+ population. (F and G) Quantification of CD4+ (F) and CD8+ (G) T cells, shown as percentages of tumor-infiltrating lymphocytes in MB49 tumors. (H) Analysis of CD4+FoxP3+ Treg cells as a percentage of tumor-infiltrating CD4+ T cells. (I–L) Analysis of granzyme B+ (I), IFN-γ+ (J), and TNF-α+ (K) CD8+ T cells and expression of annexin V (L) CD8+ T cells as percentages of tumor-infiltrating CD8+ T cells in MB49 tumors (n = 10). (M–P) The expression levels of TIM-3, LAG-3, Tox, and NR4A1 on the gated intratumoral CD8+PD-1+ T cells were analyzed. Representative flow images (top panels) and data from 5 pairs of mice are shown. Data are shown as mean ± SD. Statistical significance was determined using 1-way ANOVA for A and unpaired 2-tailed Student’s t test for the remaining panels. *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts